awmsg logo



darunavir (Prezista®)


Reference No. 2580

Publication date:
11/03/2015


Appraisal information

darunavir (Prezista®) 800 mg film-coated tablet
darunavir (Prezista®) 400 mg film-coated tablet
darunavir (Prezista®) 100 mg/ml oral suspension


Company: Janssen-Cilag Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 10/03/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, darunavir (Prezista®) cannot be endorsed for use within NHS Wales co-administered with cobicistat in combination with other antiretroviral (ART) medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adult patients.
Statement of Advice (SOA)
Download